A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 mcg/Actuation Compared With Nasonex® Nasal Spray 50 mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR)

• Status: Completed
• Trial end date: 2012-10-01

Summary

The objectives of this study is to demonstrate bioequivalence (comparable safety and efficacy) of the Test product to the Reference in the treatment of subjects seasonal allergic rhinitis.

• Phase: Phase 3

Details

• Lead Sponsor: Padagis LLC; Perrigo Company
• Treatments: Mometasone Furoate